Introduction {#s1}
============

Kawasaki disease (KD) is an acute self-limited disorder characterized by systemic vasculitis and predominantly occurs in early childhood ([@B1], [@B2]). The etiology of KD remains unknown and there are no specific diagnostic tests. Consequently, KD is characterized by fever in addition to numerous typical physical findings, including bilateral non-exudative conjunctivitis, erythema of the lips and. oral mucosa, changes in extremities, rashes, cervical lymphadenopathy and laboratory evidence of a systemic inflammatory response ([@B3], [@B4]). Coronary artery abnormality (CAA) is the most serious complication occurring in 15--25% of untreated patients and is a persistent highlight in KD research ([@B3])

Intravenous immunoglobulin (IVIG) is widely administered as the initial first-line treatment and some patients with a high risk of CAA are treated with adjunctive therapy such as corticosteroids and infliximab. However, despite these interventions, the reported incidence of CAA rate still exceeds 30% in some literatures. It is therefore very important to determine the potential risk factors of CAA in children with KD. Accordingly, previous research studies created a series of scoring systems to predict IVIG-resistant KD, considered as an important risk factor for CAA and the development of CAA in Japanese patients, such as the Harada, Kobayashi, Sano and Egami scoring systems ([@B5]--[@B8]). However, these systems were not as sensitive and specific in other populations as they were in the Japanese population ([@B9]). Moreover, these systems incorporate too many indicators and have never been systematically reviewed in detail except for a study concerning the incomplete presentation of KD and a meta-analysis investigating CAA risk factors in Chinese children ([@B10], [@B11]). Therefore, we conducted a systematic review and meta-analysis to investigate the risk factors of CAA in children with KD by analyzing the most up-to-date observational studies.

Materials and Methods {#s2}
=====================

Study Design
------------

This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement ([Checklist S1](#SM1){ref-type="supplementary-material"}) and was registered in the International Prospective Register of Systematic Reviews (reference number: CRD42018076512).

Participants
------------

Our analysis represented two groups: the control group---the KD patients without CAA, and the CAA group---the patients with onset of KD and CAA found in a given period of medical follow-up.

Search Strategy
---------------

We conducted a systematic literature search using electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, and the National Institutes of Health Clinical Trial Databases up to the 16th May 2018. We also searched OvidMedline from 1946 to 16th May 2018. The search strategy used Medical Subject Headings (MeSH) terms or Emtree thesaurus terms combined with keywords for \[(Mucocutaneous Lymph Node Syndrome) and (Coronary Artery)\]. There was no language restriction. In addition, we manually searched the reference lists of original and review articles for further articles of interest. Some texts were unavailable online; in these cases, we attempted to contact the authors via email.

Inclusion and Exclusion Criteria
--------------------------------

Our analysis included observational studies which fulfilled the following criteria: (1) Study participants were children diagnosed with KD, including both CKD and IKD; (2) All participants diagnosed with KD met the specific criteria published by the Japan Kawasaki Disease Research Committee (4th or 5th revised edition) or the American Heart Association (2001, 2004, or 2017 edition); (3) CAA was one of the outcome measures and was detected by ultrasonic cardiography as an existing abnormal body surface area adjusted by z-scores or abnormal internal lumen diameter according to criteria published by the Japanese Ministry of Health, American Heart Association, or by Chinese literature ([@B3], [@B12]); (4) Risk factors for CAA were investigated with no restriction to specific subgroups; (5) The study reported the odds ratio (OR) adjusted for at least one potential confounder and 95% confidence intervals (CIs) or allowed for the calculation of these parameters from the raw data presented in the article and (6) The article was written in English.

We excluded studies that examined risk factors for CAA in animal populations. We also excluded studies that were restricted to a specific clinical subgroup of KD patients, such as IVIG-resistant KD, atypical KD, recurrent KD or KD in pregnant women. We also excluded case reports, case series, reviews, letters, commentaries, conference papers and studies relating to the pathogenesis and genetics of KD.

Data Extraction and Quality Assessment
--------------------------------------

For each eligible study, two investigators (Fan Yan and Bo Pan) independently extracted the following information: author names, publication year, study design, follow-up duration (by echocardiography), study duration, study location, sample size, total number of CAA cases, diagnostic criteria used for KD, diagnostic criteria used for CAA, the definition of IVIG-resistant KD, risk factors and the methods used for statistical analysis. Quality assessments were also independently conducted by the two investigators (Fan Yan and Bo Pan) using the Newcastle-Ottawa Quality Assessment Scale for case control or cohort studies ([Checklist S2](#SM2){ref-type="supplementary-material"}, [Supporting Tables 1](#SM4){ref-type="supplementary-material"}, [2](#SM5){ref-type="supplementary-material"}); disagreements were resolved by group discussions.

Statistical Analysis
--------------------

To control confounders, we included studies reporting estimates which adjusted for at least one potential confounder in their analysis; this strategy has been used in previous literature ([@B13]). We believe that this is a feasible approach for eliminating some publications with low evidence levels. When a reported risk factor was evaluated by three or more studies, considering the intrinsic differences of study design, we combined the adjusted ORs and 95% CIs with the random effects model to estimate pooled ORs and associated 95% CIs. The I^2^ statistic was used to investigate the heterogeneity across studies; an I^2^ value of \<25% and \>50% was considered to indicate low and high levels of heterogeneity, respectively ([@B14]). We also performed sensitivity analysis to assess the robustness of our results by omitting a single study in turn. We also conducted the Egger regression asymmetry test and the Begg test to detect the presence of publication bias; this analysis showed that male gender was the only factor contributing to publication bias (all other factors were found in fewer than 10 studies). Statistical analyses were performed using STATA version 15 (StataCorp, College Station, TX).

Results {#s3}
=======

In total, our initial search identified 1,970 articles. After removing duplicates and reviewing the titles and abstracts, 184 studies were potentially eligible for inclusion. After assessing the full text, 33 studies were found to conform to our specific inclusion criteria. Finally, 21 of the 33 studies were included in our meta-analysis; collectively, these studies included 26,684 participants, of which 4,461 were diagnosed with CAA, contributing 9 risk factors investigated in more than two studies ([Figure 1](#F1){ref-type="fig"}). Specific characteristics of these data are summarized in [Table 1](#T1){ref-type="table"}.

![Flow diagram of studies screened in the meta-analysis.](fped-07-00374-g0001){#F1}

###### 

Summary of the included studies for quantitative synthesis.

  **Study**                      **Study design**   **Duration of following-up (by echocardiogram)**   **Study duration**          **Study location**   **Population sample size**   **Total number of CAA**   **Diagnostic criteria of KD**   **Diagnostic criteria of CAA**   **Define of IVIG-resistant KD**                                                                                      **Risk factors**                                                                                                                                          **Method of statistical analysis**   **NOS score**
  ------------------------------ ------------------ -------------------------------------------------- --------------------------- -------------------- ---------------------------- ------------------------- ------------------------------- -------------------------------- -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ---------------
  Yeo et al. ([@B15])            Case-control       At least 2 months                                  2001--2006                  Korea                136                          16                        AHA2004                         JMH                              ND                                                                                                                   Days of fever, number of symptoms                                                                                                                         Logistic regression analysis         7
  Hamza et al. ([@B16])          Case-control       Eight weeks                                        2012--2016                  Egypt                64                           34                        AHA2017                         Z score                          ND                                                                                                                   Platelet count                                                                                                                                            Logistic regression analysis         7
  Wilder et al. ([@B17])         Case-control       ND                                                 1991--2002                  America              324                          21                        AHA2004                         Z score                          ND                                                                                                                   Diagnosis after illness day 10                                                                                                                            Logistic regression analysis         7
  Weng et al. ([@B18])           Cohort study       Eight weeks                                        1993--2009                  Taiwan               2,116                        81                        AHA2004                         JMH                              Fever for 3 days after initial IVIG                                                                                  Neutrophil count,Dose of IVIG, platelet count                                                                                                             Logistic regression analysis         7
  Tajima et al. ([@B19])         Case-control       1 month                                            2006--2012                  Japan                100                          13                        JKDRC                           JMH                              A second Dose IVIG                                                                                                   Delayed IVIG (≥6 days), IVIG-resistant                                                                                                                    Logistic regression analysis         7
  Song et al. ([@B20])           Case-control       At least 2 months                                  2001--2007                  Korea                221                          30                        AHA2004                         JMH                              fever for 2 days after initial IVIG                                                                                  Number of symptoms, Post-IVIG fever, Harada score                                                                                                         Logistic regression analysis         7
  Sabharwal et al. ([@B21])      Case-control       6--8 weeks                                         1990--2007                  Canada               1,374                        266                       AHA2004                         JMH                              Absence of fever within 36 h after initial IVIG                                                                      Age, male, duration of fever before diagnosis, albumin level, hemoglobin level, platelet count, IVIG-resistant                                            Logistic regression analysis         8
  Ruan et al. ([@B22])           Case-control       1 month                                            2003--2009                  China                1,370                        486                       AHA2004                         JMH                              ND                                                                                                                   Age (\<6 months), Male, Time of IVIG, IVIG dose, platelet count and ESR                                                                                   Logistic regression analysis         7
  Qiu et al. ([@B23])            Cohort study       ND                                                 2009--2014                  China                930                          179                       Similar to JKDRC                Chinese literatures criteria     ND                                                                                                                   Treatment time, treatment time 10 days                                                                                                                    Logistic regression analysis         7
  Patel et al. ([@B24])          Case-control       ND                                                 1994--2008                  Denmark              284                          37                        Similar to AHA2004              AHA                              ND                                                                                                                   Age, male, time of IVIG (\>10 days)                                                                                                                       Logistic regression analysis         7
  Kim et al. ([@B25])            Case-control       At least 2 months.                                 2001--2005                  Korea                285                          19                        AHA2001                         JMH                              ND                                                                                                                   Total days of fever \>8 days                                                                                                                              Logistic regression analysis         7
  Young et al. ([@B26])          Cohort study       6--8 weeks                                         2005--2013                  Korea                703                          266                       AHA2004                         Z score                          Received more than one dose of IVIG                                                                                  Male, fever duration (≥8 days), CRP (≥7 mg/dl), WBC count (\>12 ×103/μL)                                                                                  Logistic regression analysis         8
  Ghelani et al. ([@B27])        Case-control       ND                                                 2000--2002 and 2007--2009   America              203                          33                        AHA2004                         Z score or JMH                   Fever after one dose of IVIG and administration of additional IVIG or use of corticosteroids or TNF-alpha blockers   ESR, refractory Kawasaki disease                                                                                                                          Logistic regression analysis         7
  Chen et al. ([@B28])           Case-control       1 month                                            2008--2012                  China                2,302                        365                       JKDRC                           JMH                              ND                                                                                                                   Male, age (≤ 1 year), IVIG unresponsiveness, time of IVIG                                                                                                 Logistic regression analysis         7
  Lega et al. ([@B29])           Case-control       6--8 weeks                                         1988--2007                  France               194                          64                        AHA2004                         AHA                              Fever ≥36 h after complete IVIG infusion                                                                             Male, Age, PE, Hemoglobin level, IVIG resistance                                                                                                          Logistic regression analysis         7
  Boudiaf and Achir ([@B30])     Case-control       4--6 weeks                                         2005--2014                  Algeria              133                          30                        AHA2004                         Z score                          ND                                                                                                                   Duration of fever (\>10 days), platelet count (\>450,000/mm^3.^)                                                                                          Logistic regression analysis         8
  Berdej-Szczot et al. ([@B9])   Case-control       No clear description                               2003--2016                  Poland               73                           13                        AHA                             AHA                              Fever \>36 h after IVIG                                                                                              Delay diagnosis, platelet count, additional symptom                                                                                                       Logistic regression analysis         8
  Kim et al. ([@B31])            Case-control       ND                                                 2012--2014                  Korea                5,151                        524                       AHA2004                         JMH                              A second dose of IVIG                                                                                                CRP                                                                                                                                                       Logistic regression analysis         7
  Xu et al. ([@B32])             Case-control       3 months                                           2009--2012                  China                422                          83                        JKDRC                           Chinese literatures Criteria     ND                                                                                                                   RDW (\>14.55%), IVIG resistance,Fever duration (\>14 days)                                                                                                Logistic regression analysis         8
  Callinan et al. ([@B33])       Case-control       ND                                                 2000--2009                  America              1,843                        341                       Similar to AHA2004              AHA                              ND                                                                                                                   Male, age, race, time of IVIG (\>5 days)                                                                                                                  Logistic regression analysis         7
  Kim et al. ([@B34])            Cohort study       3 months                                           ND                          Korea                8,456                        1,560                     AHA2004                         Z score or JMH                   Existence of second-line treatment                                                                                   Male, age, fever duration, incomplete presentation, recurrent illness, high/medium-dose ASA, non-response to first-line treatment, total bilirubin, CRP   Logistic regression analysis         6

*NOS, Newcastle-Ottawa Quality Assessment Scale; AHA, American Heart Association; JMH, Japanese Ministry of Health; ND, no description; Z score, body surface area adjusted z-scores; JKDRC, Japan Kawasaki Disease Research Committee; ESR, erythrocyte sedimentation rate erythrocyte sedimentation rate; PE, pericardial effusion; CRP, C-reactive protein; RWD, red blood cell distribution width*.

Risk Factors
------------

### Gender

Meta-analysis of 10 studies that estimated the association between male gender and CAA identified that males had a significantly higher risk for CAA (OR, 1.75; 95% CI, 1.59--1.92), with no evidence of heterogeneity (I^2^ = 0%; *P* = 0.732) ([Figure 2](#F2){ref-type="fig"}).

![Pooled odds ratio for CAA by gender (male vs. female).](fped-07-00374-g0002){#F2}

### IVIG Resistance

Pooled estimates from eight studies revealed that IVIG resistance markedly increased the risk for CAA (OR, 3.43; 95% CI, 2.07--5.67). However, there was significant heterogeneity between these eight studies (I^2^ = 76.7%; *P* = 0.000). Subgroup analysis showed that a follow-up duration of \>1 month was an increased risk factor for CAA (OR, 2.19; 95% CI, 1.48--3.24) with acceptable levels of heterogeneity (I^2^ = 47.8%; *P* = 0.105). A follow-up duration of ≤ 1 month was associated with an increased risk for CAA (OR, 6.16; 95% CI, 3.79--10.00) with low levels of heterogeneity (I^2^ = 0%; *P* = 0.560) ([Figure 3](#F3){ref-type="fig"}).

![Pooled odds ratio for CAA by IVIG-resistance (subgroup analysis basing on duration of following-up).](fped-07-00374-g0003){#F3}

### IVIG Treatment Beyond 10 Days of Onset of Symptoms

Meta-analysis of three studies showed that IVIG treatment beyond 10 days of onset of symptoms was associated with a significantly higher risk for CAA (OR, 3.65; 95% CI 2.23--5.97) with low levels of heterogeneity (I^2^ = 1.8%; *P* = 0.361) ([Figure 4](#F4){ref-type="fig"}).

![Pooled odds ratio for CAA by time of initial IVIG treatment (IVIG \> 10 days vs. IVIG ≤ 10 days).](fped-07-00374-g0004){#F4}

### C-Reactive Protein (CRP)

Meta-analysis of pooled estimates from four studies revealed that a 1 mg/L increase in CRP levels was associated with a 0.02-fold increase in risk for CAA (OR, 1.02; 95% CI 1.01--1.02); with low levels of heterogeneity (I^2^ = 0.0%; *P* = 0.441) ([Figure 5](#F5){ref-type="fig"}).

![Pooled odds ratio for CAA by CRP (mg/L).](fped-07-00374-g0005){#F5}

### The Number of Symptoms

We investigated three studies which attempted to identify an association between the number of presenting symptoms and CAA. An increasing number of the five typical symptoms of KD was shown to represent a significant protective factor for CAA (OR, 0.47; 95% CI, 0.33--0.66), with no evidence of heterogeneity (I^2^ = 0.0%; *P* = 0.753) ([Figure 6](#F6){ref-type="fig"}).

![Pooled odds ratio for CAA by number of the five typical symptoms of KD.](fped-07-00374-g0006){#F6}

### Other Factors

Our analysis identified several factors that were not significantly associated with CAA, including the interval between KD onset and IVIG administration (OR, 1.17; 95% CI, 0.99--1.38), platelet count (OR, 1.00; 95% CI, 1.00--1.01), the duration of fever (OR, 1.12; 95% CI, 0.99--1.27) and total bilirubin (OR, 1.06; 95% CI, 0.96--1.16) ([Figure 7](#F7){ref-type="fig"}).

![Pooled odds ratios for CAA by other factors.](fped-07-00374-g0007){#F7}

Discussion {#s4}
==========

CAA is a commonly encountered and serious complication of KD and is considered as a leading cause of acquired heart disease in children. Identifying patients at high risk of developing CAA at an early stage after the onset of KD is important for determining a more intensive treatment, the duration of follow-up and targeted research studies aimed at identifying new therapeutic methods for KD. In this meta-analysis, we identified five factors, based on good evidence that were strongly associated with CAA: male gender, IVIG resistance, IVIG treatment beyond 10 days of onset of symptoms, increased CRP levels, and the number of presenting symptoms. To the best of our knowledge, our study is the first meta-analysis to comprehensively investigate the risk factors associated with CAA. Only two other related studies have been published: one investigated the incomplete presentation of KD as a risk factor for CAA, the other investigated risk factors for CAA in Chinese children but with non-convincing evidence ([@B10], [@B11]).

While previous studies failed to determine an association between CAA and gender ([@B35], [@B36]), we successfully identified male gender as a strong risk factor for CAA; this difference is likely to be due to the increasing number of multicenter studies being reported with large sample sizes. Epidemiological surveys, carried out in different biogeographical regions, also identified higher incidence rates of KD in males, the boys with KD outnumbered the girls with KD by the ratio approximately 1.5--1.7:1 ([@B37], [@B38]). Until now, there is no convincing explanation for this gender bias, although Kobayashi and Dallaire noted that healthy male children tended to have larger coronary arteries than female children ([@B39], [@B40]), thus making the diagnosis of KD and CAA easier in males when using the same diagnostic criteria. There are no obvious differences in terms of estrogen level when compared between genders in children, consequently it is difficult to explain the incidence of CAA in children with KD as an autoimmune disease by estrogen levels alone, as is the case for some autoimmune diseases in adults ([@B41]). However, it has been demonstrated that different genders express variable levels of miRNA expression and that these differences may play a role in the immune response and autoimmune diseases ([@B42], [@B43]).

IVIG treatment is a well-established primary treatment measure for KD, and several studies have linked IVIG factors (such as dose and brand) with a higher risk of CAA ([@B18], [@B44]). We found that IVIG resistance and IVIG treatment beyond 10 days of onset of symptoms was associated with an increased risk for CAA. IVIG is considered to alleviate coronary injury by regulating the immune system, including the reduction of cytokine levels and the suppression of endothelial cell activation ([@B45], [@B46]). However, studies have reported IVIG resistance rates as high as 18--22%; accordingly, several scoring systems have been developed to predict IVIG-resistant KD. Because CAA usually occurs 7--10 days after the onset of KD onset ([@B47], [@B48]), the AHA published guidelines in 2004 which stated that "therapy should be instituted within the first 10 days of illness and, if possible, within 7 days of illness." However, some researchers believe that the status of the illness can potentially exert influence on the association between delayed IVIG treatment and CAA. For example, Qiu observed higher CRP levels and ESR in patients in which IVIG treatment was delayed ([@B23]). However, delayed IVIG treatment can cause increased CRP levels and ESR, and there is no good evidence to determine the causal factor between these factors. In contrast, higher CRP levels and ESR represent a more aggressive inflammatory response, causing a more typical manifestation of the illness with advanced intervention by IVIG treatment. Further studies are now required to clarify whether there is a correlation between the status of KD and delayed IVIG treatment.

We also noticed that patients with a 1 month follow-up period showed an obvious increase in the risk of CAA compared with those with a follow-up duration of \>1 month among the IVIG-resistant population. AHA guidelines recommend that echocardiographic evaluation is recommended at the time of diagnosis, at 2 weeks, and at 6--8 weeks after the onset of disease. In a previous study, Tajima and Chen conducted echocardiographic examinations before and after IVIG treatment and 1 month after the diagnosis of KD ([@B19], [@B28]); this suggested that echocardiographic evaluations should be carried out more frequently within 1 month of the onset of KD than those recommended by the AHA guidelines. This could explain the differences between subgroups. Based on these findings, we attempted to verify whether this difference also existed in other populations. Unfortunately, with the limited number of studies included for other risk factors, we were only able to carry out the same subgroup analysis in the male population. However, in situations where studies included in our subgroup analysis were somewhat similar to the IVIG-resistant population, we found no noticeable difference in the risk of CAA when compared between shorter and longer follow-up periods (OR, 1.68; 95% CI, 1.37--2.06 vs. OR, 1.74; 95% CI, 1.55--1.96) ([Supporting Figure 1](#SM3){ref-type="supplementary-material"}). In summary, children with KD who were resistant to IVIG appeared to be more likely to develop CAA within 1 month after KD onset than the general population, even compared to patients with other risk factors for CAA. As a consequence, there are potential risks for the misdiagnosis of CAA when echocardiography is not carried out frequently. Whether echocardiography should be performed more often within 1 month of KD onset in an IVIG-resistant population remains to be confirmed by future studies.

Our meta-analysis found an apparently increased risk of CAA in children with elevated CRP levels. However, this did not appear to be a neglectable risk factor with a magnitude of 10 mg/L increasing frequently. When considered as a categorical variable, as in the present study and many others, an elevated CRP level is an important risk factor of CAA ([@B5], [@B26], [@B49]). Furthermore, some recent studies that have investigated the association between atherosclerosis and inflammatory status clearly recognized the fact that CRP is also a reliable marker of inflammation and the prediction of coronary events ([@B50]--[@B52]). However, in another study, Kim studied the genetic loci that influence the levels of CRP and identified a CRP locus that is associated with high CRP levels but without affecting the development of CAA ([@B53]). However, this result may have been due to the small sample size and the fact that this previous study focused only upon a single race (Korean); it is also possible that some other underlying cause may influence the development of CAA. Furthermore, one has to consider genotypic and phenotypic diversity and irrelevant factors associated with potential confounding factors, such as gender, the duration of IVIG treatment, and the number of symptoms. One may therefore speculate that determining the primary characteristics of individuals rather than the genetic features of KD is the key in making a specific and sensitive prediction regarding CAA.

Although we did not acquire sufficient studies with which to perform a meta-analysis for the relationship between atypical KD and CAA development, we still identified that more number of the five typical symptoms of KD was a strong protective factor for CAA. However, some previous studies have stated that delays in diagnosis and IVIG treatment are associated with atypical forms of KD ([@B54], [@B55]). Furthermore, children of a younger age have consistently been associated with atypical KD ([@B24], [@B29]). However, in all three of the studies included in our meta-analysis, no significant differences were identified in terms of age and/or interval between KD onset and IVIG administration when compared between CAA(+) and CAA(--) patients. Even after adjusting for such factors, more number of symptoms was clearly a protective factor of CAA. It seems reasonable to suggest that a lower number of symptoms relates to the manifestation of an immature or dysfunctional immune response during the onset of disease.

Although the interval between KD onset and IVIG administration, platelet count, and the duration of fever were not expected to show an obvious relationship with the development of CAA, the lower values of the narrow confidence intervals for these factors were very close to 1.0. Given that we could only include a limited number of studies to investigate these factors, it is possible that our final results could easily be changed by introducing more studies into our meta-analysis. As shown in [Figure 7](#F7){ref-type="fig"}, the study reported Hamza was responsible for negative results in our meta-analysis relating to the interval between KD onset and the administration of IVIG and the duration of fever. Although this study scored 7 stars on the Newcastle-Ottawa Quality Assessment Scale, the sample size was small (64 participants); this may have had an impact upon the on the accuracy of this research. As platelet counts can be as high as 150,000 to 450,000 platelets per microliter of blood, it is difficult to distinguish a remarkable effect with a 1,000-platelet increase in platelet count. Consequently, we considered that the adoption of an appropriate cut-off point could be helpful, as in previous studies ([@B18], [@B30], [@B56]). Hence, we cannot deny a potential connection between platelet count and CAA development, and further research is now needed to determine a stable relationship between these two factors. With regards to total bilirubin, only three previous studies have considered the potential role of bilirubin in CAA; these studies yield contradictory findings and therefore there is a lack of good evidence to support a potential relationship between these factors. We were unable to perform meta-analysis for some important continuous variables, such as lymphopenia, neutrophils, and eosinophils. This was because the cut-off point for these factors varied across different studies. In order to study risk factors in a more appropriate manner, it would be more meaningful for future studies to acquire uniform cut-off values for such continuous variables.

Strengths and Limitations
-------------------------

Our systematic review has several strengths. This is the first systematic review to comprehensively investigate the risk factors for CAA in children with KD. We used a strict search strategy to screen six databases, including PubMed, Embase, Web of Science, Cochrane Library, National Institutes of Health Clinical Trial Databases and OvidMedline. Based on the Newcastle-Ottawa Scale (NOS), 20/21 included studies scored ≥7 stars, suggested high-quality studies. We included a range of publications involving different ethnic populations from across the world to ensure the applicability of our findings and to investigate a wide range of risk factors for CAA. Furthermore, the application of adjusted ORs helped us to avoid the influence of confounding variables, at least in part. We also determined the heterogeneity between the studies included in sub-group analysis and found that apart from IVIG resistance, all other factors showed low levels of heterogeneity. Our sensitivity analysis showed that the sequential omission of a single study did not significantly influence the observed results and the magnitude of effects.

There are some important limitations to this systematic review that need to be considered. First, there are some differences in the criteria used to diagnose CAA. Second, although all of the publications involved in our meta-analysis were of high quality, all of these studies featured data that was acquired retrospectively. Thus, without cautious interpretation, these outcomes could exert a negative impact. Considering the limited number of studies for some factors, the accuracy and validity of the relationship between these factors and CAA may also be questionable. Besides, because of the intrinsic differences in the design of included studies, such as study types, duration of follow-up and so on, potential bias could not be completely ruled out. Finally, in terms of the assessment of publication bias, we were only able to show that there was no apparent publication bias with respect to male gender when using the Egger regression asymmetry test and the Begg test; we did not have a sufficient sample size to carry out similar tests for the other factors.

Conclusions {#s5}
===========

Although a number of indicators have been identified to predict the development of CAA development in pediatric KD patients, these studies have never been systematically reviewed. This can reduce the accuracy of prediction and create difficulties in applying these indicators in clinical scenarios. Our present study confirmed that gender, IVIG resistance, IVIG treatment beyond 10 days of onset of symptomsand increased CRP levels are all significant risk factors for CAA. We also identified reliable evidence to support the fact that more number of presenting symptoms is a protective factor against CAA. We recommend that pediatricians should consider these five reliable factors. By more accurate prediction, and earlier preventative treatment for high risk patients, we can expect a reduction in CAA rates. Further research is now needed to investigate the association between CAA and other factors including the interval between KD onset and IVIG administration, platelet count and the duration of fever. Future research should also aim to determine whether echocardiography should be performed more frequently within 1 month of the onset of KD in IVIG-resistant patients.
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